BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29056549)

  • 1. Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma.
    Li L; Li W; Wang C; Yan X; Wang Y; Niu C; Zhang X; Li M; Tian H; Yao C; Jin H; Han F; Xu D; Han W; Li D; Cui J
    Cytotherapy; 2018 Jan; 20(1):134-148. PubMed ID: 29056549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
    Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
    Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
    BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma.
    Cui J; Li L; Wang C; Jin H; Yao C; Wang Y; Li D; Tian H; Niu C; Wang G; Han W; Xu J; Chen J; Li W
    Cytotherapy; 2015 Jul; 17(7):979-88. PubMed ID: 25890480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
    Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
    Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
    Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Short-Term Efficacy of Irreversible Electroporation and Allogenic Natural Killer Cell Immunotherapy Combination in the Treatment of Patients with Unresectable Primary Liver Cancer.
    Yang Y; Qin Z; Du D; Wu Y; Qiu S; Mu F; Xu K; Chen J
    Cardiovasc Intervent Radiol; 2019 Jan; 42(1):48-59. PubMed ID: 30151798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
    Tallerico R; Todaro M; Di Franco S; Maccalli C; Garofalo C; Sottile R; Palmieri C; Tirinato L; Pangigadde PN; La Rocca R; Mandelboim O; Stassi G; Di Fabrizio E; Parmiani G; Moretta A; Dieli F; Kärre K; Carbone E
    J Immunol; 2013 Mar; 190(5):2381-90. PubMed ID: 23345327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
    Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
    Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.
    Bae WK; Lee BC; Kim HJ; Lee JJ; Chung IJ; Cho SB; Koh YS
    Front Immunol; 2022; 13():879452. PubMed ID: 35720374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant FOLFOX chemotherapy combined with radiotherapy followed by radical resection in patients with locally advanced colon cancer.
    Huang CM; Huang MY; Ma CJ; Yeh Y-; Tsai HL; Huang CW; Huang CJ; Wang JY
    Radiat Oncol; 2017 Mar; 12(1):48. PubMed ID: 28270172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
    Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
    Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
    Ishikawa T; Okayama T; Sakamoto N; Ideno M; Oka K; Enoki T; Mineno J; Yoshida N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Kokura S; Uno K; Naito Y; Itoh Y
    Int J Cancer; 2018 Jun; 142(12):2599-2609. PubMed ID: 29388200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of carcinoma, apoptosis, and cell-death-related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells.
    Ray AK; Somanchi SS; Dastgheyb N; Aquino-Lopez A; Cobanoglu ZE; Geier B; Lee DA
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27783. PubMed ID: 31304677
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Jung IH; Kim DH; Yoo DK; Baek SY; Jeong SH; Jung DE; Park SW; Chung YY
    In Vivo; 2018; 32(4):771-781. PubMed ID: 29936458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
    Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
    Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell crossmatch: functional analysis of inhibitory killer immunoglobulin-like receptors and their HLA ligands.
    Han M; Fallena M; Guo Y; Stastny P
    Hum Immunol; 2007 Jun; 68(6):507-13. PubMed ID: 17509450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.